BioMarin Pharmaceuticals BMRN Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's total costs & expenses?
- BioMarin Pharmaceuticals (BMRN) reported total costs & expenses of $636.57M in Q1 2026.
- How has BioMarin Pharmaceuticals's total costs & expenses changed year-over-year?
- BioMarin Pharmaceuticals's total costs & expenses increased by 22.1% year-over-year, from $521.25M to $636.57M.
- What is the long-term trend for BioMarin Pharmaceuticals's total costs & expenses?
- Over 4 years (2021 to 2025), BioMarin Pharmaceuticals's total costs & expenses has grown at a 9.9% compound annual growth rate (CAGR), from $1.93B to $2.81B.
- What does total costs & expenses mean?
- The sum of all costs incurred by the company to operate during a specific period.
- How do you interpret total costs & expenses?
- Rising total costs relative to revenue indicate margin compression, while stable or declining costs suggest improved operational leverage.
- How does total costs & expenses compare across companies?
- Used to compare overall cost structures and operating leverage against industry peers.